Sequenom Enters Clinical Collaboration With Seoul National University

SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with Seoul National University Hospital (SNUH). SNUH and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood in a series of research studies targeting several hundred patients across a wide variety of cancer types.

"We are looking forward to collaborating with Sequenom on the clinical evaluation of their new liquid biopsy assay," said Yung-Jue Bang, MD, PhD, Professor in the Department of Internal Medicine at Seoul National University Hospital. "We believe that liquid biopsy has the potential to significantly improve clinical care in a variety of cancer management settings."

"This is Sequenom's first oncology collaboration with a leading medical center in Asia," said Daniel Grosu, M.D., Chief Medical Officer at Sequenom. "We are excited to work with SNUH on evaluating our liquid biopsy assay in a substantial number of clinical samples. Among other objectives, this study will enable us to comprehensively analyze the genomic alterations concordance between tissue and blood in different cancers."

Sequenom is currently developing a Research Use Only (RUO) assay with an initial focus on the detection and molecular profiling of late stage non-hematologic malignancies in settings where tissue biopsies are not available or are too risky to obtain.  The assay will cover a breadth of cancer types by analyzing over 100 cancer-related genes that are included in professional society guidelines, linked to targeted therapies currently in clinical trials, or part of well-documented cancer pathways. This clinical research study will aim to enroll several hundred patients across 10 different cancer types.

About Seoul National University Hospital 
Through the historical tradition of Jejungwon and Daehan Hospital, Seoul National University Hospital (SNUH), as the representative medical center of Korea, has been heralded as a national development engine raising the nation's healthcare system to world-class standards in the medical sciences, as well as medical education, research, and patient care. Currently, SNUH consists of different branches that have grown over the years as an extension of the main branch located in Daehak-ro: SNU Bundang Hospital, SMG-SNU Boramae Medical Center, SNUH Healthcare System Gangnam Center, SNU Children's Hospital, and SNU Cancer Hospital.

About Sequenom   
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management information. To learn how Sequenom is interpreting the genome to improve your life, visit www.sequenom.com.

SEQUENOM^®, Sequenom Laboratories, HerediT^® CF, HerediT^® UNIVERSAL, VisibiliT, MaterniT21^® PLUS, MaterniT GENOME, and NextView, are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking  
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the development of innovative products and services, the belief that liquid biopsy has the potential to significantly improve clinical care in a variety of cancer management settings, the ability of the study to comprehensively analyze the genomic alterations concordance between tissue and blood in different cancers, the ability of the assay to cover a breadth of cancer types by analyzing over 100 cancer-related genes and the ability to enroll several hundred patients across 10 different cancer types for the study. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Quarterly Report on Form 10-Q and other documents subsequently filed with or furnished to the Securities and Exchange Commission.  All forward-looking statements contained in this press release speak only as of the date on which they were made.  The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequenom-enters-clinical-collaboration-with-seoul-national-university-hospital-300153838.html

SOURCE Sequenom, Inc.